CCIA
ZVRA icon

Campbell & Co Investment Adviser’s Zevra Therapeutics ZVRA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$988K Buy
68,869
+44,970
+188% +$500K 0.05% 547
2026
Q1 		$223K Sell
23,899
-14,696
-38% -$132K 0.01% 947
2025
Q4 		$346K Buy
38,595
+964
+3% +$9.12K 0.02% 941
2025
Q3 		$358K Sell
37,631
-45,614
-55% -$457K 0.03% 845
2025
Q2 		$733K Buy
+83,245
New +$676K 0.05% 637

Other funds holding ZVRA

RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
IA
IFG Advisors St. Louis, Missouri $725M AUM 27.52% 1-Year Est. Return
CAM
Carret Asset Management New York $1.14B AUM 35.33% 1-Year Est. Return
ES
Element Squared Minneapolis, Minnesota $201M AUM 27.42% 1-Year Est. Return

Campbell & Co Investment Adviser's ZVRA Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its Zevra Therapeutics (ZVRA) stake by 188% in Q2 2026, buying an estimated $500K and bringing the position to 68,869 shares worth $988K. The position accounts for 0.05% of the portfolio, ranked #547.

Campbell & Co Investment Adviser first reported a position in ZVRA in Q2 2025 and has held it in 5 quarters since. 36 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Campbell & Co Investment Adviser held 68,869 shares of Zevra Therapeutics worth $988K as of Q2 2026.
  • Campbell & Co Investment Adviser bought 44,970 Zevra Therapeutics shares in Q2 2026, an estimated $500K.
  • Zevra Therapeutics made up 0.05% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #547 holding.
  • Campbell & Co Investment Adviser first reported a position in Zevra Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 36 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.